Entero Therapeutics, Inc.

ENTONASDAQHealthcare

$2.85

$-0.15(-5.00%)

Market Cap$13582331

P/E Ratio—

52W High$5.84

52W Low$0.969

Avg Volume216K

Open$3.00

Beta1.19

Overview

Entero Therapeutics, Inc. (ENTO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ENTO · free cash flow · updated Jun 9, 2026

Core FCF metrics

ENTO · FCF · TTM · margin & CAGR

Free cash flow was −$5.7M for FY2025 (fiscal year ending 2025-12-31), up 38.1% year-over-year

FY2025 Free Cash Flow−$5.7M▲ +38.1% YoY

Trailing 12M (TTM)−$6.7Mtrailing 4 quarters sum

FCF Margin< −999%−$5.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ENTO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$5.7M(0M)−$5.7M▲ +38.1%—

FY2024−$9.2M(0M)−$9.2M▲ +28.4%—

FY2023−$12.4M(1M)−$12.9M▲ +42.4%—

FY2022−$22.3M(0M)−$22.3M▲ +47.6%—

FY2021−$32.3M(10M)−$42.6M▼ 279.6%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ENTO · P/FCF · FCF yield · FCF per share

Entero Therapeutics, Inc. (ENTO) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ENTO · cash flow statement · operating / investing / financing

For FY2025, Entero Therapeutics, Inc. generated −$5.7M in operating cash flow and spent 0M in capital expenditures, yielding −$5.7M in free cash flow.

Operating Activities

−$5.7M

Cash from core business operations

2025-12-31

Investing Activities

+$0.3M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$5.9M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$5.7M) − |CapEx| (0M) = FCF (−$5.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ENTO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Entero Therapeutics, Inc.YOU

ENTO

−$5.7M+38.1%-15731.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Entero Therapeutics, Inc. (ENTO) reported free cash flow of −$5.7M for FY2025 (fiscal year ending 2025-12-31), up 38.1% year-over-year.

Based on available data, Entero Therapeutics, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $56.554 in FY2013.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ENTO free cash flow · 8 questions

Entero Therapeutics, Inc. free cash flow was −$5.7M for FY2025, up 38.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$6.7M.

ENTO free cash flowENTO FCFENTO FCF 2025ENTO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Entero Therapeutics, Inc. · Entero Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026